Results showed an ORR of 70%, 36%, and 30% for HER-2 positive (3+ by IHC), HER-2 low (1+ or 2+ by IHC, ISH negative), and HER-2 negative (0+ by IHC) BC cohorts, respectively. This evidence concerns the gene ERBB2 and breast cancer.